CA2372960C - Compositions et procedes immunogenes anti-vih - Google Patents

Compositions et procedes immunogenes anti-vih Download PDF

Info

Publication number
CA2372960C
CA2372960C CA002372960A CA2372960A CA2372960C CA 2372960 C CA2372960 C CA 2372960C CA 002372960 A CA002372960 A CA 002372960A CA 2372960 A CA2372960 A CA 2372960A CA 2372960 C CA2372960 C CA 2372960C
Authority
CA
Canada
Prior art keywords
hiv
immunogenic composition
nucleic acid
acid molecule
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002372960A
Other languages
English (en)
Other versions
CA2372960A1 (fr
Inventor
Ronald B. Moss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Original Assignee
Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp filed Critical Immune Response Corp
Publication of CA2372960A1 publication Critical patent/CA2372960A1/fr
Application granted granted Critical
Publication of CA2372960C publication Critical patent/CA2372960C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions immunogènes qui améliorent les taux de beta -chimiokine chez le mammifère. Ces compositions immunogènes contiennent un antigène anti-VIH, une molécule d'acide nucléique isolée contenant une séquence immunostimulante et un adjuvant. L'antigène anti-VIH peut être un virus VIH totalement inactivé, dépourvu de la protéine d'enveloppe extérieure gp120. Par ailleurs, l'antigène anti-VIH peut être un virus VIH totalement inactivé, ou un antigène p24. L'invention concerne également des trousses dont les composants, une fois combinés, produisent les compositions immunogènes selon l'invention. L'invention traite également de procédés de fabrication des compositions immunogènes, en combinant un antigène anti-VIH, une molécule d'acide nucléique isolée contenant une séquence immunostimulante et un adjuvant. L'invention traite également d'un procédé permettant d'immuniser un mammifère, en lui administrant une composition immunogène contenant un antigène anti-VIH, une molécule d'acide nucléique isolée contenant une séquence immunostimulante et un adjuvant. L'invention a aussi pour objet un procédé permettant d'inhiber le SIDA, en renforçant la production de beta -chimiokine chez le mammifère, en administrant à ce dernier une composition immunogène contenant un antigène de VIH, une molécule d'acide nucléique isolée contenant une séquence immunostimulante et un adjuvant.
CA002372960A 1999-05-06 2000-05-05 Compositions et procedes immunogenes anti-vih Expired - Fee Related CA2372960C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13276299P 1999-05-06 1999-05-06
US60/132,762 1999-05-06
US15066799P 1999-08-25 1999-08-25
US60/150,667 1999-08-25
PCT/US2000/012495 WO2000067787A2 (fr) 1999-05-06 2000-05-05 Compositions et procedes immunogenes anti-vih

Publications (2)

Publication Number Publication Date
CA2372960A1 CA2372960A1 (fr) 2000-11-16
CA2372960C true CA2372960C (fr) 2006-03-28

Family

ID=26830710

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002372960A Expired - Fee Related CA2372960C (fr) 1999-05-06 2000-05-05 Compositions et procedes immunogenes anti-vih

Country Status (8)

Country Link
EP (1) EP1176978A2 (fr)
AP (1) AP1891A (fr)
AU (1) AU4992900A (fr)
BR (1) BR0010323A (fr)
CA (1) CA2372960C (fr)
CR (1) CR6491A (fr)
OA (1) OA11937A (fr)
WO (1) WO2000067787A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
WO2000048630A1 (fr) 1999-02-17 2000-08-24 Csl Limited Complexes immunogenes et methodes y relatives
ES2250151T3 (es) * 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. Uso de cpg como adyuvante de vacuna contra vih.
CA2430691A1 (fr) 2000-12-27 2002-07-04 Dynavax Technologies Corporation Polynucleotides immunomodulants et methodes d'utilisation correspondantes
WO2002058726A1 (fr) * 2001-01-26 2002-08-01 The Immune Response Corporation Procede de traitement d'un individu infecte par le vih en associant l'immunisation a une interruption structuree du traitement antiretroviral
CN100334228C (zh) 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2388049A1 (fr) 2002-05-30 2003-11-30 Immunotech S.A. Oligonucleotides immunostimulateurs et utilisations connexes
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CA2494508A1 (fr) * 2002-07-03 2004-01-15 Coley Pharmaceutical Group, Inc. Compositions d'acide nucleique destinees a stimuler les reponses immunitaires
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
ATE544466T1 (de) 2002-10-29 2012-02-15 Coley Pharm Group Inc Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
WO2004053104A2 (fr) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. Acides nucleiques 5'cpg et leurs methodes d'utilisation
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
DK1575977T3 (da) 2002-12-23 2009-11-09 Dynavax Tech Corp Oligonukleotider med Immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
CA2535527A1 (fr) * 2003-08-28 2005-03-10 The Immune Response Corporation Compositions immunogenes contre le vih et methodes correspondantes
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2010051820A1 (fr) * 2008-11-10 2010-05-14 Aarhus Universitet Vaccination contre multiplexée par la cytokine
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753688B2 (en) * 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
PT1003850E (pt) * 1997-06-06 2009-08-13 Dynavax Tech Corp Inibidores da actividade de sequências de adn imunoestimulantes

Also Published As

Publication number Publication date
AU4992900A (en) 2000-11-21
AP2001002300A0 (en) 2001-12-31
CA2372960A1 (fr) 2000-11-16
AP1891A (en) 2008-09-23
WO2000067787A3 (fr) 2001-04-26
WO2000067787A2 (fr) 2000-11-16
BR0010323A (pt) 2002-01-08
CR6491A (es) 2005-05-31
OA11937A (en) 2006-04-12
EP1176978A2 (fr) 2002-02-06

Similar Documents

Publication Publication Date Title
US6737066B1 (en) HIV immunogenic compositions and methods
CA2372960C (fr) Compositions et procedes immunogenes anti-vih
Boyer et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial
Graham et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120: a randomized, double-blind trial
ZA200602246B (en) Immunogenic HIV compositions and related methods
EP1578766B1 (fr) Vaccins polyvalents a adn contre la glycoproteine du hiv-1 primaire et procedes de vaccination
NO314588B1 (no) HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
Fast et al. Human trials of experimental AIDS vaccines
AU2005222909B2 (en) Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
Zolla-Pazner et al. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines
Valentine et al. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with⩾ 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)
US20030044428A1 (en) Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment
US20080026448A1 (en) Production of HIV
Silvera et al. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques
ZA200108559B (en) HIV immunogenic compositions and methods.
MXPA01010784A (en) Hiv immunogenic compositions and methods
Benferhat et al. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope
Trabattoni et al. Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice
KR20070019635A (ko) 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법
Leavell et al. Induction of serum and mucosal FIV-specific immune responses by intranasal immunization with p24Gag
WO1994002171A1 (fr) Methode prophylactique et therapeutique de lutte contre les infections retrovirales
WO1994002171A9 (fr) Methode prophylactique et therapeutique de lutte contre les infections retrovirales

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed